Ecotec is part of the Gram-Negative Antibacterials NOW (GNA NOW) consortium within the Innovative Medicine Initaitive's AMR Accelerator. © AdobeStock

Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR).

Production at Pierre Fabre Médicaments. © Pierre Fabre

French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.

German Regional Court in Düsseldorf. © Justiz NRW

German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.

© Ipsen

Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.

Ambrosia Bio co-founder and CEO Ziv Zwighaft (left) and Olivier Rolland, Executive Director at TWB. © Toulouse White Biotech

At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.

BioNTainers. © BioBTech SE

BioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this year’s end toKigall.

© Canify AG

In an effort to become a major player in Europe’s growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG.  

Unilever's state of the art manufacturing site in Dubai. © Unilever

Under the $120m deal, Genomatica and Unilever will scale plant- and waste-based alternative to palm oil and fossil fuels.

Roche obtained from European Medicine Agency (EMA) a special authorization (conditional approval) for new bispecific antibody Lunsumio for treatment of relapsed or refractory follicular (R/R) lymphoma (FL) – a B-cell cancer. Data for authorization are based on a survey from a phase I/II trail. The high unmet need of this indication led to that early decision, it is said.

First structural description of butyrophilins. ©J Biol Chem. 2012 Sep 21; 287(39): 3278032790, Daniel Olive et al.

ImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments are invested already. Invus and The Leukemia & Lymphoma
Society Therapy Acceleration Program also joined the round as new investors.